SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected fourth-quarter outlook after its earnings reportamid soft PC demand, manufacturing constraints, and analyst downgradeshas driven a sharp selloff. Traders are divided between calling the decline an oversold buying opportunity and warning that the guidance reset could bring further losses.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks earnings beat, upbeat outlook and announced stock split have been overshadowed by a sharp selloff alongside tech and memory shares. Traders are split between calling the drop an overreaction to strong results and warning that slowing growth and potentially peaking memory prices signal a cyclical downturn.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq selloff has QQQ traders focused on tech earnings and concerns that heavy AI spending may not deliver returns, with Alphabets results and rising capital-expenditure plans cited as pressure points. The community is split between fears of an AI-bubble unwind and forced selling, and dip-buyers looking for a rebound; midterm and geopolitical speculation also appears.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits sharp selloff is centered on a softer fourth-quarter outlook and falling Google search referrals, which have raised concerns about user growth; plans to test a logged-in experience also prompt fears that casual traffic could weaken further. Traders debate whether these are lasting growth risks or whether the reaction is excessive given the earnings beat, with some buyers calling shares oversold.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader tech and semiconductor selloff as Amazons heavy AI spending and Intels weak outlook intensify concerns that hyperscaler capital expenditures may not earn adequate returns. Traders are split between warnings that the AI buildout is a bubble and dip buyers who argue demand for Nvidias chips remains strong.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is plunging as semiconductor and tech shares sell off, with traders frequently blaming Intels weak outlook and slowing PC demand for weighing on the sector; broader concerns about tech earnings and the AI trade are also in the discussion. The sharp decline has sparked a split between dip buyers expecting a rebound and traders warning of further losses, with SOXLs 3 leverage amplifying the volatility.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broad tech and semiconductor selloff, as Intels weak outlook and scrutiny of AI spending returns weigh on chip stocks. Traders disagree on whether the drop signals broader AI valuation concerns or creates an opportunity for AMD to gain from Intels struggles, with the companys earnings report a key focus.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff tied to disappointing tech results and concerns that heavy AI spending may not pay off has traders debating whether the AI-led rally is unwinding; rising oil and Iran-war fears and midterm uncertainty add to the anxiety. Many are bearish and see more downside, while others are buying the dip or looking for a rebound.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure ahead of its quarterly earnings report, with traders citing analyst price-target cuts and concerns about advertising growth and competition, amplified by weak signals from other ad-supported companies. The community is split between viewing the steep selloff as a valuation opportunity and fearing that results or guidance could disappoint amid broader weakness in tech stocks.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations and management raised its delivery outlook as the R2 ramped, prompting bullish reactions and renewed interest in the companys growth prospects. Traders remain divided because the shares struggled to hold their gains, with skeptics focusing on continued cash burn and the uncertain path to profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on October 26, 2026, the...

Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the third quarter...

Zura Bio to Participate in the Cantor Global Healthcare Conference

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will...

Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the...

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinicalstage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter...

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy

William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.read more...

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced several tibulizumab program updates. Zura...

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (Zura or the Company), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious...

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Ltd. is a clinical-stage, multi-asset immunology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Zura Bio Ltd - Ordinary Shares - Class A

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well

Equity

Neutral Sentiment

Novartis (NVS) on Monday announced positive results from its late-stage trials evaluating its investigational drug Ianalumab in adults with active Sjögren's disease.Ianalumab is a novel fully human monoclonal antibody being investigated for its potential to treat various B-cell-driven autoimmune diseases. The drug’s mechanism of action targets B cells in two ways: combining B cell depletion and interruption of BAFF-R-mediated signals of B cell function and survival.Guggenheim said the positive updates give evidence that BAFF-signaling disruption and B cell depletion are "a valid approach" for hard-to-treat autoimmune diseases, which has a positive read-through for Zura Bio (ZURA). Shares of <a href="https://stocktwits.com/symbol/ZURA">Zura</a>, which Guggenheim deems "significantly undervalued," traded 3% higher at the time of writing.Novartis <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease">said</a> that its two late-stage trials for Sjögren's disease met the primary endpoint of demonstrating statistically significant improvements in disease activity. Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_12_02_03_PM_png_fdf22daf95.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.“These Phase III studies mark a significant milestone. We look forward to engaging with health authorities to discuss these findings in the near future,” said Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis.Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease, the company said, while adding that it plans to submit the drug to health authorities globally.NYSE-listed shares of the company traded 1% higher at the time of writing.Ianalumab originated from Novartis’ early collaboration with MorphoSys AG, a company which it later acquired in 2024. In clinical trials, Ianalumab showed promising efficacy and a favorable safety profile in Sjögren’s disease, systemic lupus erythematosus, and immune thrombocytopenia.While NVS shares are up by 21% this year, ZURA is down 42%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/avantor-responds-to-activist-investor-engine-capital-letter/chru67IRde5">Avantor Responds To Activist Investor Engine Capital’s Letter: ‘Acting With Urgency To Strengthen Growth’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZURA Zura Bio Ltd - Ordinary Shares - Class A

Fundamentals

Latest ZURA News